atuveciclib

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].

Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is the (S)-enantiomer of BAY-1143572. Atuveciclib S-Enantiomer is a potent and selective CDK9 inhibitor, which inhibits CDK9 / CycT1 with an IC 50 of 16 nM.

Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib, which is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.

Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.